New Two-Pronged cancer drug enters human trials

NCT ID NCT04977453

Summary

This study is testing the safety and effectiveness of a new investigational drug called GI-101 for people with advanced or metastatic solid tumors. The drug is designed to work in two ways to help the immune system fight cancer. Researchers will test it alone and in combination with two other approved cancer drugs to find the best dose and see if it can help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

    Contact

  • Carolina Biooncology Institute

    RECRUITING

    Huntersville, North Carolina, 28078, United States

    Contact

  • Chungnam National University Hospital

    RECRUITING

    Daejeon, Daejeon, 65015, South Korea

    Contact

  • Korea University Anam Hospital

    RECRUITING

    Seoul, Seongbuk-gu, 02841, South Korea

    Contact

  • The Catholic University of Korea St. Vincent's Hospital

    RECRUITING

    Suwon, Kyeonggi-do, 16247, South Korea

    Contact

  • Tisch Cancer Institute (TCI), Icahn School of Medicine

    RECRUITING

    New York, New York, 10029-5674, United States

    Contact

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, 03722, South Korea

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.